Monitoring CAR T cells in peripheral blood by flow cytometry following Tisagenlecleucel in Fundeni Clinical Institute, Bucharest

Abstract

Introduction: Over the past few years, the introduction of chimeric antigen receptor (CAR) T-cell therapy by the FDA has shown remarkable success in treating various hematologic malignancies. However, the limited response and resistance observed in some patients have hindered its broader application.

Keywords

• car t
• tisagenlecleucel
• cellular therapy
• flow cytometry